Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHAPhoR
- Development stage
- Preclinical
- Lead developer
- CHA Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
CHAPhoR is an investigational **cell therapy** developed by **CHABiotech** for the treatment of **Age-related Macular Degeneration (AMD)**. The product consists of **retinal progenitor cells (RPCs)** designed to restore or support retinal function. The therapeutic approach utilizes a cell-replacement and regenerative mechanism, where the progenitor cells are intended to integrate into the retinal environment and replace damaged or lost cells associated with AMD progression. CHAPhoR is currently in the preclinical stage of development, focusing on establishing safety and efficacy in supporting retinal cell health and visual restoration.
Beyond the preview
Go deeper on CHAPhoR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHAPhoR.